Treatment of Alzheimer's disease: Current status and new perspectives

Elio Scarpini*, Philip Scheltens, Howard Feldman

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

Alzheimer's disease (AD) is the most common neurodegenerative disorder and the most prevalent cause of dementia with ageing. Pharmacological treatment of AD is based on the use of acetylcholinesterase inhibitors, which have beneficial effects on cognitive, functional, and behavioural symptoms of the disease, but their role in AD pathogenesis is unknown. Other pharmacological therapies are becoming available - including the recently approved drug memantine, an NMDA channel blocker indicated for advanced AD. Here, we review clinical features of the available cholinesterase inhibitors (donepezil, rivastigmine, and galantamine) including their pharmacological properties, the evidence for switching from one agent to another, "head to head" studies, and the emerging evidence for the use of memantine in AD. New therapeutic approaches - including those more closely targeted to the pathogenesis of the disease - will also be reviewed. These potentially disease modifying treatments include amyloid-β-peptide vaccination, secretase inhibitors, cholesterol-lowering drugs, metal chelators, and anti-inflammatory agents.

Original languageEnglish
Pages (from-to)539-547
Number of pages9
JournalLancet Neurology
Volume2
Issue number9
DOIs
Publication statusPublished - 1 Sep 2003

Cite this